PE20020082A1 - PHARMACEUTICAL COMPOSITION INCLUDING AN ALDOSTERONE-SYNTHASE INHIBITOR AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST (AT1) - Google Patents

PHARMACEUTICAL COMPOSITION INCLUDING AN ALDOSTERONE-SYNTHASE INHIBITOR AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST (AT1)

Info

Publication number
PE20020082A1
PE20020082A1 PE2001000328A PE2001000328A PE20020082A1 PE 20020082 A1 PE20020082 A1 PE 20020082A1 PE 2001000328 A PE2001000328 A PE 2001000328A PE 2001000328 A PE2001000328 A PE 2001000328A PE 20020082 A1 PE20020082 A1 PE 20020082A1
Authority
PE
Peru
Prior art keywords
angiotensin
pharmaceutical composition
composition including
synthase inhibitor
receptor antagonist
Prior art date
Application number
PE2001000328A
Other languages
Spanish (es)
Inventor
Ronald Edward Steele
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20020082A1 publication Critical patent/PE20020082A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE AL USO DE UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) INHIBIDOR DE ALDOSTERONA-SINTASA TAL COMO ANASTROZOL, FADROZOL O SU ENANTIOMERO DE FORMULA II, EXEMESTANO; b) UN ANTAGONISTA DEL RECEPTOR ANGIOTENSINA II AT1 SOLO O COMBINADO CON UN DIURETICO TAL COMO HIDROCLOROTIAZIDA; EL ANTAGONISTA DEL RECEPTOR DE AT1 ES SELECCIONADO DE VALSARTAN, LOSARTAN, CANDESARTAN, EPROSARTAN, IRBESARTAN, EL COMPUESTO DE FORMULA I, ENTRE OTROS Y c) UN VEHICULO FARMACEUTICAMENTE ACEPTABLE. LA COMPOSICION ES UTIL PARA LA PREVENCION O TRATAMIENTO DE HIPERTENSION INSUFICIENCIA CARDIACA CONGESTIVA, ATEROESCLEROSIS, RESISTENCIA A LA INSULINA, DISFUNCION ENDOTELIALIT REFERS TO THE USE OF A PHARMACEUTICAL COMPOSITION INCLUDING: a) ALDOSTERONE SYNTHASE INHIBITOR SUCH AS ANASTROZOL, FADROZOL OR ITS FORMULA II ENANTIOMER, EXEMESTANE; b) AN ANGIOTENSIN II AT1 RECEPTOR ANTAGONIST ONLY OR IN COMBINATION WITH A DIURETIC SUCH AS HYDROCHLOROTHIAZIDE; THE ANTAGONIST OF THE AT1 RECEPTOR IS SELECTED FROM VALSARTAN, LOSARTAN, CANDESARTAN, EPROSARTAN, IRBESARTAN, THE COMPOUND OF FORMULA I, AMONG OTHERS AND c) A PHARMACEUTICALLY ACCEPTABLE VEHICLE. THE COMPOSITION IS USEFUL FOR THE PREVENTION OR TREATMENT OF HYPERTENSION, CONGESTIVE HEART FAILURE, ATHEROSCLEROSIS, INSULIN RESISTANCE, ENDOTHELLIAL DYSFUNCTION

PE2001000328A 2000-04-12 2001-04-10 PHARMACEUTICAL COMPOSITION INCLUDING AN ALDOSTERONE-SYNTHASE INHIBITOR AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST (AT1) PE20020082A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19674200P 2000-04-12 2000-04-12

Publications (1)

Publication Number Publication Date
PE20020082A1 true PE20020082A1 (en) 2002-02-21

Family

ID=22726655

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000328A PE20020082A1 (en) 2000-04-12 2001-04-10 PHARMACEUTICAL COMPOSITION INCLUDING AN ALDOSTERONE-SYNTHASE INHIBITOR AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST (AT1)

Country Status (19)

Country Link
EP (1) EP1282410A2 (en)
JP (1) JP2003530343A (en)
KR (1) KR20020089437A (en)
CN (1) CN1422152A (en)
AR (1) AR032316A1 (en)
AU (2) AU7393801A (en)
BR (1) BR0110079A (en)
CA (1) CA2405895A1 (en)
HU (1) HUP0301335A3 (en)
IL (1) IL152081A0 (en)
MX (1) MXPA02010091A (en)
NO (1) NO20024920L (en)
NZ (1) NZ521855A (en)
PE (1) PE20020082A1 (en)
PL (1) PL358459A1 (en)
RU (1) RU2002129569A (en)
SK (1) SK14612002A3 (en)
WO (1) WO2001076574A2 (en)
ZA (1) ZA200208204B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1368009A2 (en) * 2000-07-27 2003-12-10 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
US6777443B2 (en) 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
KR101092279B1 (en) 2002-12-27 2011-12-13 다케다 야쿠힌 고교 가부시키가이샤 Body weight gain inhibitor
SE0300988D0 (en) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
WO2005099695A1 (en) * 2004-04-19 2005-10-27 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
ITTO20040760A1 (en) * 2004-11-03 2005-02-03 Uni Degli Studi Del Piemonte USE OF A CORTICOSTEROID IN ASSOCIATION WITH OTHER ACTIVE PRINCIPLES FOR THE TREATMENT OF VASCULAR STENOSIS AND THE PREVENTION OF VASCULAR RESTENOSIS
EP1674080A1 (en) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
CA2592091A1 (en) * 2004-12-24 2006-06-29 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
US9271963B2 (en) 2005-03-03 2016-03-01 Universitat Des Saarlandes Selective inhibitors of human corticosteroid synthases
TW200716636A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
GT200600381A (en) 2005-08-25 2007-03-28 ORGANIC COMPOUNDS
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
EP2095819A1 (en) 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
ES2582395T3 (en) 2009-05-28 2016-09-12 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
NZ596304A (en) 2009-05-28 2014-01-31 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
CA2841117A1 (en) 2011-07-08 2013-01-17 Novartis Ag 1,2-disubstituted-4-benzylamino-piperidinyl derivatives as cetp inhibitors useful for the treatment of atherosclerosis in high triglyceride subjects
UY35144A (en) 2012-11-20 2014-06-30 Novartis Ag APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT
EP2956464B1 (en) 2013-02-14 2018-03-28 Novartis AG Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
UY35670A (en) 2013-07-25 2015-02-27 Novartis Ag CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE
MX2016001021A (en) 2013-07-25 2016-08-03 Novartis Ag Bioconjugates of synthetic apelin polypeptides.
US9931372B2 (en) 2015-01-23 2018-04-03 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
JOP20190086A1 (en) 2016-10-21 2019-04-18 Novartis Ag Naphthyridinone derivatives and their use in the treatment of arrhythmia
KR102506380B1 (en) 2016-10-27 2023-03-03 다미안 파르마 에이쥐 aldosterone synthase inhibitors
UY38072A (en) 2018-02-07 2019-10-01 Novartis Ag COMPOSITIONS DERIVED FROM BUTANOIC ESTER SUBSTITUTED WITH BISPHENYL AS INHIBITORS OF NEP, COMPOSITIONS AND COMBINATIONS OF THE SAME
CA3097281A1 (en) 2018-05-03 2019-11-07 Damian Pharma Ag R-fadrozole for use in the treatment of aldostonerism
UY38485A (en) 2018-11-27 2020-06-30 Novartis Ag CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) INHIBITORS, METHOD OF TREATMENT, USE AND PREPARATION
JP2022507958A (en) 2018-11-27 2022-01-18 ノバルティス アーゲー Cyclic tetramer compound as a proprotein convertase subtilisin / kexin type 9 (PCSK9) inhibitor for the treatment of metabolic disorders
JP2022509184A (en) 2018-11-27 2022-01-20 ノバルティス アーゲー Cyclic peptide as a proprotein convertase subbutyricin / kexin type 9 (PCSK9) inhibitor for the treatment of metabolic disorders
TW202333563A (en) 2021-11-12 2023-09-01 瑞士商諾華公司 Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (en) 2021-11-23 2024-02-21 Novartis Ag NAFTYRIDINOONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252565A (en) * 1990-04-02 1993-10-12 Merrell Dow Pharmaceuticals Inc. Haloethyl-substituted steroid enzyme inhibitors
JPH0971586A (en) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd New bicyclic condensed imidazole derivative
DK0930876T3 (en) * 1996-07-22 2005-02-14 Renovo Ltd Use of compounds that promote estrogenic activity in the treatment of wounds
US5906987A (en) * 1997-03-10 1999-05-25 Schering Aktiengesellschaft And Board Of Regents Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors
FR2766821A1 (en) * 1997-07-29 1999-02-05 Sanofi Sa 1,3-OXAZOLINYL-BIPHENYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS SYNTHESIS INTERMEDIATES
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
NZ509260A (en) * 1998-07-10 2003-09-26 Novartis Ag Pharmaceutical composition containing valsartan and a calcium channel blocker

Also Published As

Publication number Publication date
PL358459A1 (en) 2004-08-09
SK14612002A3 (en) 2003-05-02
WO2001076574A3 (en) 2002-04-25
ZA200208204B (en) 2003-10-14
CA2405895A1 (en) 2001-10-18
BR0110079A (en) 2002-12-31
CN1422152A (en) 2003-06-04
HUP0301335A2 (en) 2003-08-28
AR032316A1 (en) 2003-11-05
NO20024920D0 (en) 2002-10-11
EP1282410A2 (en) 2003-02-12
MXPA02010091A (en) 2003-02-12
AU2001273938B2 (en) 2005-03-03
WO2001076574A2 (en) 2001-10-18
NO20024920L (en) 2002-11-27
NZ521855A (en) 2004-10-29
JP2003530343A (en) 2003-10-14
IL152081A0 (en) 2003-05-29
HUP0301335A3 (en) 2006-02-28
AU7393801A (en) 2001-10-23
KR20020089437A (en) 2002-11-29
RU2002129569A (en) 2004-03-27

Similar Documents

Publication Publication Date Title
PE20020082A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING AN ALDOSTERONE-SYNTHASE INHIBITOR AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST (AT1)
PE20070803A1 (en) PHARMACEUTICAL COMBINATION OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND A NEUTRAL ENDOPEPTIDASE INHIBITOR
PE107099A1 (en) COMPOSITION OF ATORVASTATINE AND AN ANTI-HYPERTENSOR
CR7548A (en) DERIVATIVES OF TRIAZOLE AS ANTAGONISTS OF THE TACHYKININ RECEIVER
PE20120315A1 (en) A PHARMACEUTICAL COMPOSITION INCLUDING CANDESARTAN, CANDESARTAN CILEXETIL, OR AZILSARTAN, COMBINED WITH AMLODIPINE
PE20081557A1 (en) SUBSTITUTE OXINDOL DERIVATIVES, DRUGS THAT UNDERSTAND THEM, AND THE USE OF THEM
WO2005011646A3 (en) Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases
CL2003002731A1 (en) COMPOUND DERIVED FROM QUINAZOLINE OF DEFINED FORMULA, ACTING AS AN INHIBITOR OF THE AURORA KINASA; COMPOSITE PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMPOUND AND USE OF THE COMPOUND; USEFUL FOR THE TREATMENT OF ENFE
PE20090654A1 (en) GALENIC FORMULATIONS CONTAINING ALISQUIREN AND VALSARTAN
MX2009014002A (en) Imidazole derivatives as ccr2 receptor antagonists.
NO20063380L (en) Triazole derivatives as vasopressin antagonists
MX2009005174A (en) 5-sulfanylmethyl-[1,2,4] triazol[1, 5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists.
RS20080510A (en) Benzimidazole derivative and use as angiotensin ii antagonist
MX2009010297A (en) Ornithine derivative.
TW200744593A (en) Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
PL1843754T3 (en) New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance
MX2007004661A (en) 1-(hetero)aryl-3-amino-pyrollidine derivatives for use as mglur3 receptor antagonists.
WO2006110884A3 (en) 2, 6-di (hetero) aryl -4-amido-pyrimidines as adenosine receptor antagonists
CA2420055A1 (en) Fibrinogen-lowering agent
WO2008056375A3 (en) Pharmaceutical formulations comprising valsartan
DOP2010000088A (en) INHIBITOR COMPOSITE OF PHOSPHORILASE OF GLICOGEN AND PHARMACEUTICAL COMPOSITION OF THE SAME.
CL2007003613A1 (en) NITRO-DERIVED COMPOUNDS, ANTAGONISTS OF THE ANGIOTENSIN II RECEIVER; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT HYPERTENSION.
EA200901295A1 (en) CRYSTALLINE 1- (CYCLOGEXYLOXYCARBONYLOXY) ETHYL-1 - (((2'-CYANODYPHENYL-4-IL) METHYL) -2-ETOXY-1H-BENZO [D] IMIDAZOLE-7-CARBOXYLATE and SOFOS
RU2006117790A (en) APPLICATION OF A PYRAZOLE DERIVATIVE FOR THE PRODUCTION OF A MEDICINE SUITABLE FOR PREVENTION AND TREATMENT OF DYSLIPIDEMIA AND DISEASES ASSOCIATED WITH DYSLIPIDEMIA AND / OR OBESITY
CL2004000379A1 (en) USE OF A PHARMACEUTICAL COMBINATION OF LERCANIDIPINE WITH A BLOCKER OF ANGIOTENSIN II RECEPTORS, SELECTED FROM OLMESARTAN, IRBESARTAN, VALSARTAN, TELMISARTAN AND LOSARTAN, TO TREAT HYPERTENSION.

Legal Events

Date Code Title Description
FC Refusal